Selective detection of histologically aggressive prostate cancer

An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial

Stephen Williams, Simpa Salami, Meredith M. Regan, Donna P. Ankerst, John T. Wei, Mark A. Rubin, Ian M. Thompson, Martin G. Sanda

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N = 635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of the Prostate Cancer Prevention Trial (N = 3833) was used to validate the generalization of the predictive model. RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57% had no cancer, 14% had indolent cancer, and 29% had aggressive cancer. Age, body mass index, family history of prostate cancer, abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P 0.1 ng/mL/cc or abnormal DRE. When PSAD is

Original languageEnglish (US)
Pages (from-to)2651-2658
Number of pages8
JournalCancer
Volume118
Issue number10
DOIs
StatePublished - May 15 2012
Externally publishedYes

Fingerprint

Prostate
Prostatic Neoplasms
Biopsy
Digital Rectal Examination
Research
Neoplasms
Prostate-Specific Antigen
National Cancer Institute (U.S.)
Body Mass Index
Survival
Therapeutics

Keywords

  • biopsy
  • clinically significant
  • indolent
  • prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Selective detection of histologically aggressive prostate cancer : An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. / Williams, Stephen; Salami, Simpa; Regan, Meredith M.; Ankerst, Donna P.; Wei, John T.; Rubin, Mark A.; Thompson, Ian M.; Sanda, Martin G.

In: Cancer, Vol. 118, No. 10, 15.05.2012, p. 2651-2658.

Research output: Contribution to journalArticle

Williams, Stephen ; Salami, Simpa ; Regan, Meredith M. ; Ankerst, Donna P. ; Wei, John T. ; Rubin, Mark A. ; Thompson, Ian M. ; Sanda, Martin G. / Selective detection of histologically aggressive prostate cancer : An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. In: Cancer. 2012 ; Vol. 118, No. 10. pp. 2651-2658.
@article{49b87b9e2bff40519415a67801e4c89d,
title = "Selective detection of histologically aggressive prostate cancer: An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial",
abstract = "BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N = 635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of the Prostate Cancer Prevention Trial (N = 3833) was used to validate the generalization of the predictive model. RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57{\%} had no cancer, 14{\%} had indolent cancer, and 29{\%} had aggressive cancer. Age, body mass index, family history of prostate cancer, abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P 0.1 ng/mL/cc or abnormal DRE. When PSAD is",
keywords = "biopsy, clinically significant, indolent, prostate cancer",
author = "Stephen Williams and Simpa Salami and Regan, {Meredith M.} and Ankerst, {Donna P.} and Wei, {John T.} and Rubin, {Mark A.} and Thompson, {Ian M.} and Sanda, {Martin G.}",
year = "2012",
month = "5",
day = "15",
doi = "10.1002/cncr.26396",
language = "English (US)",
volume = "118",
pages = "2651--2658",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Selective detection of histologically aggressive prostate cancer

T2 - An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial

AU - Williams, Stephen

AU - Salami, Simpa

AU - Regan, Meredith M.

AU - Ankerst, Donna P.

AU - Wei, John T.

AU - Rubin, Mark A.

AU - Thompson, Ian M.

AU - Sanda, Martin G.

PY - 2012/5/15

Y1 - 2012/5/15

N2 - BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N = 635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of the Prostate Cancer Prevention Trial (N = 3833) was used to validate the generalization of the predictive model. RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57% had no cancer, 14% had indolent cancer, and 29% had aggressive cancer. Age, body mass index, family history of prostate cancer, abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P 0.1 ng/mL/cc or abnormal DRE. When PSAD is

AB - BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N = 635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of the Prostate Cancer Prevention Trial (N = 3833) was used to validate the generalization of the predictive model. RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57% had no cancer, 14% had indolent cancer, and 29% had aggressive cancer. Age, body mass index, family history of prostate cancer, abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P 0.1 ng/mL/cc or abnormal DRE. When PSAD is

KW - biopsy

KW - clinically significant

KW - indolent

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84860676725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860676725&partnerID=8YFLogxK

U2 - 10.1002/cncr.26396

DO - 10.1002/cncr.26396

M3 - Article

VL - 118

SP - 2651

EP - 2658

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -